17Alpha-hydroxyprogesterone - CAS 68-96-2
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
17Alpha-hydroxyprogesterone
Catalog Number:
68-96-2
Synonyms:
Hydroxyprogesterone; (8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one;
CAS Number:
68-96-2
Description:
17α-Hydroxy Progesterone, as a metabolite of Progesterone, is an endogenous progestogen as well as chemical intermediate in the biosynthesis of other steroid hormones
Molecular Weight:
330.47
Molecular Formula:
C21H30O3
Quantity:
Grams-Kilos
Quality Standard:
Enterprise Standard
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CC(=O)C1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)O
InChI:
1S/C21H30O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h12,16-18,24H,4-11H2,1-3H3/t16-,17+,18+,19+,20+,21+/m1/s1
InChIKey:
DBPWSSGDRRHUNT-CEGNMAFCSA-N
Targets:
Others
Chemical Structure
CAS 68-96-2 17Alpha-hydroxyprogesterone

Related Products


SS5020
(CAS: 1334310-70-1)

SS5020 is a novel benzopyran antiestrogen and it exhibits no genotoxic activity to damage DNA. In addiction, SS5020 does not present significant uterotrophic po...

CAS 1256094-72-0 AI-10-49

AI-10-49
(CAS: 1256094-72-0)

AI-10-49 is a protein-protein interaction inhibitor that selectively binds to CBFβ-SMMHC and disrupts its binding to RUNX1 with a FRET IC50 of 0.26 uM.

U-75875
(CAS: 112190-24-6)

U-75875 is a protease inhibitor. It is also a peptidomimetic inhibitor and could inhibit HIV-1 gag-pol protein. It completely blocked HIV replication in human p...

CAS 68406-26-8 Ginsenoside-Rb3

Ginsenoside-Rb3
(CAS: 68406-26-8)

Ginsenoside Rb3, a natural triterpenoid saponin, possesses the effect against isoproterenol-induced myocardial injury and heart function impairment, and that th...

CAS 81-81-2 Warfarin

Warfarin
(CAS: 81-81-2)

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. It is an anticoagulant normally used in the prevention of ...

CAS 72432-03-2 Miglitol

Miglitol
(CAS: 72432-03-2)

Miglitol is an oral anti-diabetic drug.

FR 76830
(CAS: 113243-75-7)

This molecular is developed as a novel bradycardiac agent through organic synthesis.

CAS 57852-42-3 Resiniferonol 9,13,14-Orthophenylacetate

Resiniferonol 9,13,14-Orthophenylacetate
(CAS: 57852-42-3)

Resiniferonol 9,13,14-Orthophenylacetate, a 20-Deacylated derivative of resiniferatoxin and tinyatoxin, is a transient receptor potential vanilloid-1 (TRPV1) ag...

CAS 162784-72-7 7-Epi-10-oxo-docetaxel

7-Epi-10-oxo-docetaxel
(CAS: 162784-72-7)

Docetaxel Impurity

Pocapavir
(CAS: 146949-21-5)

Pocapavir has been found to be an antienterovirus agent that could probably be effctive against enterovirus infections. The Phase-II trial for Poliomyelitis has...

CAS 54706-99-9 20-Deoxyingenol

20-Deoxyingenol
(CAS: 54706-99-9)

20-Deoxyingenol is a diterpene derivative of Ingenol, isolated from the seeds of Euphorbia lathyris L., which has anti-tumor activity when used topically for th...

CAS 1665-48-1 Metaxalone

Metaxalone
(CAS: 1665-48-1)

Metaxalone is a muscle relaxant. The mechanism of action of metaxalone in humans is not fully understood. It was suggested that it acts through general central ...

CAS 70553-45-6 NS 3763

NS 3763
(CAS: 70553-45-6)

NS 3763 is a non-competitive kainate receptor antagonist of GLUK5 subunit-containing receptors (IC(50) = 1.6 microM)) without disrupting GLU(K6) subtype (IC(50)...

CP-60949-4
(CAS: 17518-97-7)

CP-60949-4, a quinazolin derivative, could be probably useful in sorts of biological studies.

SID 3712249
(CAS: 522606-67-3)

SID 3712249 is an biogenesis of microRNA-544 (miR-544) inhibitor caused apoptosis in triple negative breast cancer cells.

JNJ-2408068
(CAS: 317846-22-3)

JNJ-2408068 is a potent inhibitor of respiratory syncytial virus (RSV), exhibits potent antiviral activity with 50% effective concentrations (EC50s) of 1.4 and ...

CAS 104987-11-3 Tacrolimus (FK506)

Tacrolimus (FK506)
(CAS: 104987-11-3)

FK-506 is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP12 (FK506 binding protein) creating ...

EL-102
(CAS: 1233948-61-2)

EL102, a HIF1α inhibitor, has been found to have potential effect in restraining polymerisation of tubulin and influencing the stability of microtubule. IC50: 2...

CAS 24292-60-2 NADP disodium salt

NADP disodium salt
(CAS: 24292-60-2)

NADP disodium salt, also called as Coenzyme II, widely distributed in living matter, is a participant coenzyme in aerobic and anaerobic oxidations.

Duloxetine metabolite Para-Naphthol Dulo
(CAS: 949095-98-1)

Duloxetine metabolite Para-Naphthol Duloxetine is a metabolite of Duloxetine, which is a serotonin-norepinephrine reuptake inhibitor.

Reference Reading


1.Prevention of preterm delivery with compounded 17a-hydroxyprogesterone caproate.
Reed-Kane D Pharmd Fiacp Faca Fc1, Kirschbaum K Phd. Int J Pharm Compd. 2006 May-Jun;10(3):165-71.
17a-hydroxyprogesterone caproate is a naturally occurring metabolite of progesterone that is produced in significant quantities during pregnancy. The demand for 17a-hydroxyprogesterone caproate, the lack of a commercially available manufactured form approved by the US Food And Drug Administration, and publication of the results of a large trial to determine the effectivenss of the drug in the prevention of preterm delivery have spawned an increased interest in compounded formulations of the drug. The demand also has necessitated a review of the available literature and of past clinical studies, and a look at present and planned studies. Owing to the importance of this drug in pregnancy and the need for safety, accuracy in potency, and sterility in an intramuscular injection (the most common route of administration), compounding pharmacies must be in compliance with the United States Pharmacopeia Chapter 797 standards should they wish to compound this formulation.
2.Low basal androstenedione levels plus augmented 17alpha-hydroxyprogesterone and low dehydroepiandrosterone sulfate responses to adrenocorticotropic hormone stimulation in patients with adrenal incidentaloma.
Ozgen AG1, Bayraktar F, Yilmaz C. Endocr Pract. 2001 Nov-Dec;7(6):448-53.
OBJECTIVE: To investigate the androstenedione, 17a-hydroxyprogesterone (17-OHP), and dehydroepiandrosterone sulfate (DHEAS) basal levels and responses to adrenocorticotropic hormone (ACTH) in patients with adrenal incidentalomas in order to determine which enzyme defects are present.
3.Congenital adrenal hyperplasia due to 21-hydroxylase deficiency - management in adults.
Ambroziak U, Bednarczuk T, Ginalska-Malinowska M, Małunowicz EM, Grzechocińska B, Kamiński P, Bablok L, Przedlacki J, Bar-Andziak E. Endokrynol Pol. 2010 Jan-Feb;61(1):142-55.
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is one of the most common autosomal recessive hereditary diseases. The impairment of cortisol synthesis leads to excessive stimulation of the adrenal glands by adrenocorticotropic hormone (ACTH), adrenal hyperplasia, and excessive androgen synthesis. The syndrome is characterised by a considerable correlation between the genotype and the phenotype with the type of CYP21A2 gene mutation affecting the severity of 21-hydroxylase deficiency. The clinical manifestations of CAH in adults result from adrenocortical and adrenomedullary insufficiency, hyperandrogenism, and the adverse effects of glucocorticosteroids used for the treatment of the condition. Non-classic CAH may sometimes be asymptomatic. In patients with classic CAH obesity, hyperinsulinaemia, insulin resistance, and hyperleptinaemia are more often seen than in the general population. These abnormalities promote the development of metabolic syndrome and its sequelae, including endothelial dysfunction, and cardiovascular disease.
4.In vitro-metabolism of 3H-progesterone in human testicular tissue: IV Before and after long-term gonadotrophin treatment; including one 47, XYY-male.
Berg AA, Kjessler B. Acta Endocrinol Suppl (Copenh). 1976;207:49-59.
Certain defects in the intratesticular androgen biogenetic system may lead to a significant impairment of gonadal function in total in the human male. In the present investigation, four males with impaired reproductive performance were analysed before and after long term treatment with gonadotrophic hormones with regard to their in vitro metabolism of 3H-progesterone in testicular incubates; one of whom representing the first instance of an XYY-male studied in some detail with regard to intratesticular steroidogenesis. A steroid metabolisc pattern of an "immature" type, i.e., possibly indicating a relative understimulation of the gonads by gonadotrophic hormones, in vivo, was found in one of the four patients, i.e., the XYY-male, inspite of normal levels of gonadotrophic hormones in the peripheral circulation. Gametic output was found to increase significantly during the course of gonadotrophin substitution therapy, and the individual steroid metabolic pattern also changed drastically towards a more mature type subsequent to therapy.